Who Got These Clots
Six instances of TTS, including one death, had been reported at the time of the pause. All of these cases involved women between ages 18 and 48 years old. Symptoms of TTS began after receiving the J& J COVID-19 vaccine.
At the time of writing, nine further instances of TTS have been reported, according to the . Two of these additional cases were associated with deaths.
Arent Cold Storage And Stability Some Of The Reasons The Rollout Of The Vaccine Has Been A Challenge
We have the capacity in a lot of the U.S. to get the cold storage mRNA vaccines out, but it can be a challenge in rural areas. When you start talking about a vaccine that is more stable and only involves a single shot, this is great news. The easier it is to give, the more people were going to vaccinate in the U.S. But this is also true internationally, where delivering a tricky mRNA vaccine can be a challenge in some areas due to the cold storage requirements.
How Long After Getting The J& j Vaccine Can Blood Clots Occur
This condition can occur four to 42 days after vaccination.
Symptoms may include a severe headache, visual changes, abdominal pain, nausea and vomiting, back pain, shortness of breath, leg pain or swelling, the appearance of round brown-purple spots, easy bruising, or bleeding, according to the American Society of Hematology.
Also Check: Does Cvs Have Tdap Vaccine
Are There Rare Side Effects
Some much rarer side effects were also observed during the phase 3 clinical trial. These occurred in very few people.
Out of the 21,895 individuals who received the vaccine, only 7 people had a severe adverse effect that was considered to be related to vaccination. This is about 0.03 percent of trial participants in the vaccine group. These effects included:
- severe allergic reaction
- post-vaccination syndrome, which includes headache, fever, and weakness
- brachial radiculitis
The investigators did note some blood clot events. For example, 11 blood clotting events were observed in the vaccine group compared with 3 in the placebo group. Most of these participants had underlying conditions that increase the risk of blood clots.
The J& J COVID-19 vaccine is a viral vector vaccine. This means that it uses a virus to deliver the vaccine components. Lets examine this in more detail.
Us Fda Recommends Pause On Johnson & Johnson Vaccine Amid Blood Clot Concerns
Johnson & Johnson’s single-dose COVID-19 vaccine has hit a stumbling block in the United States as regulators begin investigating reports of blood clots, weeks before the first shipment of the jabs are expected to arrive in Canada.
The U.S. Centers for Disease Control and Prevention and the Food and Drug Administration said Tuesday they were investigating clots in six women that occurred in the days after vaccination. The agencies are recommending pausing the use of the Johnson & Johnson jab in the country.
It’s the second COVID vaccine to be investigated for a possible link to blood clotting after several European countries temporarily halted use of the Oxford-AstraZeneca vaccine for the same reason last month.
Canada approved the Johnson & Johnson vaccine in early March, but manufacturing issues have delayed shipments.Health Canada said Tuesday it is investigating the latest reports, and Prime Minister Justin Trudeau noted the country is still on track to receive its first shipment at the end of April.
The company said it’s delaying rolling out its vaccine in Europe amid the U.S. investigation.
The Johnson & Johnson reports appear similar to the rare type of clotting disorder that European authorities said last week is possibly linked to AstraZeneca. The European Medicines Agency has said the benefits of receiving the AstraZeneca jab outweigh the potential risks.
Here’s how the four vaccines work:
Messenger RNA Vaccines
Don’t Miss: Does Cvs Have Tdap Vaccine
Choose An Mrna Vaccine
vaccine recommendations to state that either of the two mRNA vaccines is preferred over the J& J vaccine.
This change comes after a review of an updated risk-benefit assessment of the COVID-19 vaccines. The CDC based their decision on two main factors:
- the higher vaccine effectiveness of the mRNA vaccines compared to the J& J vaccine
- the risk of serious side effects like thrombosis with thrombocytopenia syndrome and Guillain-Barré syndrome that are associated with the J& J vaccine, but not with the mRNA vaccines
However, the reviewers also noted that the benefits of vaccination still outweigh the risks of remaining unvaccinated. As such, the J& J vaccine can still be used in people who cannot receive an mRNA vaccine.
The J& j Vaccine Is Robustly Protective And New Data Suggest It Defends Against The Delta Variant Too
Two weeks ago, virologist Angela Rasmussen received a dose of the Pfizer-BioNTech coronavirus vaccine to boost her immune system, which was already primed by a Johnson & Johnson shot.
No U.S. health agency has recommended this vaccine combo. And Rasmussen, a research scientist at the University of Saskatchewans Vaccine and Infectious Disease Organization in Canada, remains confident in data that show one J& J dose will prevent her from getting hospitalized with covid-19, the illness caused by the virus.
But she was concerned about a rare post-vaccination breakthrough infection though not because she worried it would make her sick. Instead, if she were exposed and her immune system did not roundly defeat the infection, she feared any surviving pathogens may have the opportunity to evolve into more resistant strains. The emergence of the delta variant, a version of the coronavirus that more easily spreads from person to person, troubled Rasmussen. The Pfizer shot, she said, could reinforce her protection against that variant or help stop her from spreading it.
Because more scientific reports involve mRNA vaccines rather than J& J vaccines, Rasmussen said she thinks people who received the J& J shot are feeling left behind. Some of those people may be wondering whether they, too, need boosters.
Recommended Reading: Does Cvs Have Tdap Vaccine
Effectiveness Against The Delta Variant
There is currently limited data available showing how effective the vaccine is at protecting against the Delta variant.
According to information released by Johnson & Johnson, the vaccine was found be 85% effective against severe/critical disease from COVID-19, including that caused by the Delta variant. Data from a clinical study published in The New England Journal of Medicine also supports this finding.
In December 2021 the Centers for Disease Control and Prevention endorsed updated recommendations made by the Advisory Committee on Immunization Practices for the prevention of COVID-19, expressing a clinical preference for individuals to receive an mRNA COVID-19 vaccine over Johnson & Johnsons COVID-19 vaccine.
This updated CDC recommendation follows similar recommendations from other countries, including Canada and the United Kingdom, said the CDC. Given the current state of the pandemic both here and around the world, the ACIP reaffirmed that receiving any vaccine is better than being unvaccinated.
Results from the Sisonke trial, which examined 480,000 South African health workers who received the one-dose vaccine, suggest that it is up to 95% effective in preventing death from the Delta variant and up to 71% effective against hospitalization. Although promising, this new data from the trial has yet to be peer-reviewed or published in a scientific journal.
Controversy Regarding Blood Clots
Similar to the AstraZeneca COVID-19 vaccine Vaxzevria the Johnson & Johnson vaccine was put on hold after eight cases of a rare blood clotting disorder, in combination with low blood platelet counts, were found in the vaccine recipients.
Most of these cases of thrombosis with thrombocytopenia were extremely rare types, including cerebral venous sinus thrombosis , which occurs in the brain.
All eight cases occurred within 21 days of vaccination in people under the age of 60. Also, the majority of the eight vaccine recipients who experienced these side effects were women.
The EMAs safety assessment committee concluded on April 20 that the vaccines label should include blood clots as a potential rare side effect and state that the benefits of the vaccine outweigh these risks.
Authorities are uncertain what causes these cases of blood clotting. They suggest that it may be a triggered immune response similar to a rare condition of thrombocytopenia induced by heparin, which is a blood thinner.
CVST is rare in the general population, occurring at a rate of around 5 in 1 million people annually. Reports indicate that there have been eight cases among more than 7 million people who have received the Johnson & Johnson vaccine.
The benefits of receiving the vaccine outweigh the risk of blood clots and the risk of the complications that can come with COVID-19.
However, the pause is likely to have caused some hesitancy toward the vaccine and has slowed rollout.
Read Also: Does Cvs Have Tdap Vaccine
Can I Be Charged An Administration Fee For Receiving The Covid
No. At this time, the provider cannot charge you for a vaccine dose and you cannot be charged an out-of-pocket vaccine administration fee or any other fee if only receiving a COVID-19 vaccination. However, vaccination providers may seek appropriate reimbursement from a program or plan that covers COVID-19 vaccine administration fees for the vaccine recipient .
How Is It Different From The Moderna And Pfizer Vaccines
The most basic difference is that the Johnson & Johnson vaccine is an adenovirus vector vaccine, while the Moderna and Pfizer vaccines are both mRNA vaccines. Messenger RNA vaccines use genetic instructions from the coronavirus to tell a persons cells to make the spike protein, but these dont use another virus as a vector. There are many practical differences, too.
Both of the mRNA-based vaccines require two shots. The Johnson & Johnson vaccine requires only a single dose. This is key when vaccines are in short supply.
The Johnson & Johnson vaccine can also be stored at much warmer temperatures than the mRNA vaccines. The mRNA vaccines must be shipped and stored at belowfreezing or subzero temperatures and require a complicated cold chain to safely distribute them. The Johnson & Johnson vaccine can be stored for at least three months in a regular refrigerator, making it much easier to use and distribute.
Recommended Reading: Does Cvs Have Tdap Vaccine
If Youre Somewhat Less Protected Against Mild And Moderate Covid
No vaccine can prevent all COVID-19 infections. To minimize the chances of transmitting the virus even after youve been fully vaccinated, Gandhi suggests avoiding contact with unvaccinated people if you experience possible COVID-19 symptoms.
The good news is that vaccination seems to reduce viral load in the small percentage of people who still become infected. Preliminarydata from Israel of the Pfizer vaccine suggest that if you catch COVID-19 after vaccination, youre likely to harbor less virus, making you less likely to transmit.
I think its going to end up being quite hard to transmit virus after youve been vaccinated, even if you are exposed, because of the low viral load in your nose, said Gandhi. Which is one of the reasons the CDC has said that vaccinated people do not need to quarantine after exposure if asymptomatic. Thats really based on that data.
Isnt A Main Advantage Of The Johnson & Johnson Vaccine That Youre Less Likely To Get Severely Ill From Covid
In the study population of almost 44,000 people, some of whom received a placebo and didnt get the vaccine, the Johnson & Johnson vaccine was 85% effective in preventing hospitalizations and death. Even if the vaccine wasnt 100% effective at preventing disease, it looks like it reduces severe disease. That is really what you want from a vaccine.
Read Also: Does Cvs Have Tdap Vaccine
Should I Choose One Vaccine Over Another
Although the overall efficacy of the Moderna and Pfizer vaccines is higher than the Johnson & Johnson vaccine, you should not wait until you have your choice of vaccine which is likely a long way off anyway. The Johnson & Johnson vaccine is nearly as good as the mRNA-based vaccines at preventing serious disease, and thats what really matters.
The Johnson & Johnson vaccine and other viral-vector vaccines like the one from AstraZeneca are particularly important for the global vaccination effort. From a public health perspective, its important to have multiple COVID-19 vaccines, and the Johnson & Johnson vaccine is a very welcome addition to the vaccine arsenal. It doesnt require a freezer, making it much easier to ship and store. Its a one-shot vaccine, making logistics much easier compared with organizing two doses per person.
As many people as possible need to be vaccinated as quickly as possible to limit the development of new coronavirus variants. Johnson & Johnson is expected to ship out nearly four million doses as soon as the FDA grants emergency use authorization. Having a third authorized vaccine in the U.S. will be a big step towards meeting vaccination demand and stopping this pandemic.
Ive Heard The Johnson & Johnson Vaccine Is Less Effective Than The Pfizer And Moderna Vaccines Your Thoughts
We have really done ourselves a disservice with how wildly effective the Pfizer and Moderna vaccines are. No one is going to say they dont want a highly effective vaccine. We are all grateful, but at the start of the pandemic if you said you were going to produce a 60% effective vaccine, that would have been beyond most peoples wildest dreams. Compare that to the flu , which can be 50% to 60% effective some years.
The Johnson & Johnson vaccine was found to be 72% effective at preventing moderate to severe cases of COVID-19. Across the board, it was around 66%. I think part of the reason is because it was studied later in the pandemic. Now there are more of these variants out there. The Johnson & Johnson vaccine was less effective in South Africa, where one of the variants has appeared. It was 57% in South Africa. I think if you were to test the Moderna and Pfizer vaccines now, they might be less effective because of the variants.
Also Check: Does Cvs Have Tdap Vaccine
How Viral Vector Vaccines Work
COVID-19 viral vector vaccines use a modified version of a different virus to deliver important instructions to our cells.
How Much Will A Covid
Any doses purchased by the U.S. government are free to its citizens. While the facility or agency that offers the vaccine may request reimbursement from insurance plans or a public health program for an administration fee, no one can be charged any fees to receive a COVID-19 vaccine or be denied a vaccine if they do not have health insurance.
Recommended Reading: Cvs Whooping Cough Vaccine
What You Need To Know
- Viral vector vaccines use a modified version of a virus that is different from the virus being targeted to deliver important instructions to our cells. The modified version of the virus is called a vector virus.
- Like all vaccines, viral vector vaccines benefit people who get vaccinated by giving them protection against diseases like COVID-19 without them having to risk the serious consequences of getting sick.
- Learn more about getting your vaccine.
The Johnson & Johnson Janssen vaccine, a viral vector vaccine, is among the COVID-19 vaccines authorized for emergency use in the United States.
There Are Three Safe Vaccines
Dont get caught up necessarily on the numbers game, because its a safe and effective vaccine and what we need is to have as many effective vaccines as possible, said Dr. Irons. Rather than focusing on efficacy rates, accept the fact that now you have three highly effective vaccines.
We do have three safe and highly effective COVID vaccines. COVID vaccines continue to maintain high protection against severe disease, hospitalization and death, said Dr. Fryhofer. However, we are seeing breakthrough infections. Its all about waning immunitywith time and with the Delta variant, along with concern about vaccine effectiveness against future variants of concern.
Studies presented to FDA and others reviewed by ACIP show some waning of immunity with time, she added. For example, a recent study published in Sept. 28 MMWR looked at COVID vaccine effectiveness against hospitalization from mid-March through mid-August. VEvaccine effectivenesswas higher for Moderna vaccine at 93% as compared to Pfizer-BioNTech vaccine at 88%.
Pfizer vaccine effectiveness declined significantly from 91% down to 77%at more than four months after the second vaccine dose. Moderna vaccine effectiveness did not wane as much as Pfizer, Dr. Fryhofer explained. VE for both mRNA vaccines was higher than Janssen. Janssens single dose vaccine had the lowest vaccine effectiveness at 71%.
Recommended Reading: Tdap Shot At Cvs